AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its pipeline centers on Ampligen® (rintatolimod), a nucleic-acid based immune modulator studied across indications including ME/CFS and immuno-oncology, and it also has an FDA-approved interferon product, Alferon N Injection. The company’s commercialization approach relies heavily on partnering—licensing, collaborations, and potential joint ventures—to obtain regulatory approvals and build commercial reach in specific territories. AIM currently generates only limited revenue (e.g., via an Ampligen cost recovery program) and positions partnerships and external funding as key enablers of development and commercialization.
−13 212,5 %
−15 861,4 %
−48,2 %
0.53
0.53
| % | |
|---|---|
| Ampligen® (rintatolimod) pipeline | 70% R&D and clinical development of Ampligen across ME/CFS, oncology and viral-disease applications. |
| Partnering and licensing arrangements | 15% Territory-based licensing/collaboration/joint-venture efforts to obtain approvals and commercialize products. |
| Ampligen Cost Recovery / expanded access supply | 10% Limited patient access programs where participants support costs, producing small, variable revenue. |
| Alferon N Injection | 5% FDA-approved natural interferon product with commercialization dependent on partners and market access. |
AIM’s near-term customers are a mix of (1) patients and clinical sites participating in access programs that support...
License or co-develop Ampligen (and potentially Alferon) to fund trials, secure approvals, and commercialize in defined territories.
Access Ampligen for severe disease settings (e.g., ME/CFS) with participation levels driving small, fluctuating revenue.
Obtain Ampligen supply for preclinical/clinical research (e.g., antiviral studies) to generate data supporting future development.
Distribute and commercialize Ampligen locally (historically Argentina via GP Pharm/Filaxis) subject to regulatory approvals and contract renewals.
AIM is headquartered in Ocala, Florida and operates primarily as a U.S.-based R&D organization while pursuing...
AIM’s strategy emphasizes finding senior co-development partners with the capital and expertise to run clinical...
AIM indicates it lacks adequate funds to independently fund trials and commercialization.
Argentina is a concrete example of partner-led regulatory/commercial execution and could extend to other countries.
Clinical and preclinical data are key to attracting partners and enabling regulatory pathways in new indications.
Commercial viability depends on defensible IP and reliable, higher-volume supply capabilities.
AIM faces high development and financing risk because it reports no material operating revenues and states it does not...
The company states it does not have adequate funds to meet anticipated cash needs and does not generate material revenues.
Strategy relies on licensing/collaborations/JVs; partner priorities can change and agreements may not be renewed.
Reported Ampligen cost recovery revenue fluctuates with patient participation and is not a stable commercial base.
IOVA · Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
IMNM · Pharmaceutical Preparations
IMUX · Pharmaceutical Preparations
ALMS · Pharmaceutical Preparations
IOBTQ · Pharmaceutical Preparations
CADL · Biological Products, (No Diagnostic Substances)
: 11/08/2026